NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
December 4, 2007 • Volume 4 / Number 31 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

The information and links on this page are no longer being updated and are provided for reference purposes only.


70 Years of Excellence in Cancer Research

If Memory Serves...

NIH had two personnel systems when NCI was created: the Commissioned Corps of the Public Health Service and the Federal Civil Service. (Read more)

For more information about the birth of NCI, go to

Hawk to Join M.D. Anderson
Dr. Ernest T. Hawk, director of NCI's Office of Centers, Training and Resources (OCTR), has been named vice president and division head for Cancer Prevention and Population Sciences at the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Hawk joined NCI's Division of Cancer Prevention (DCP) in 1993.

Since 2004, Dr. Hawk has served as director of OCTR. Prior to this, he was chief of the Gastrointestinal and Other Cancers Research Group in DCP. Dr. Hawk's work in the area of nonsteroidal anti-inflammatory drugs for cancer prevention was recognized with the NCI Research Award for Distinguished Achievement in Cancer Prevention.

Dr. Hawk also co-chaired NCI's Translational Research Working Group, which drafted a plan approved by the NCAB in June 2007 proposing a series of major initiatives for the NCI to consider in the area of translational research.

Dr. Jaye L. Viner has been appointed acting director of OCTR, where she has served as the deputy director since 2006.

Dr. Hiroaki Mitsuya
Dr. Hiroaki Mitsuya
Mitsuya Receives Keio Medical Science Prize
Dr. Hiroaki Mitsuya, head of the Experimental Retrovirology Section in the HIV and AIDS Malignancy Branch in NCI's Center for Cancer Research, has been awarded the 2007 Keio Medical Science Prize. The award is presented by the Keio University Medical Science Fund and recognizes major projects that contribute to the advancement of life sciences and medicine and encourage the expansion of researcher networks. Dr. Mitsuya's work is highly regarded as a clinical breakthrough in the treatment of AIDS. He discovered that AZT inhibits HIV activity, and subsequently developed it as the first drug to treat AIDS. He also later developed the drugs ddI and ddC. The drugs have been used in clinics around the world and have dramatically improved the prognosis of HIV-infected individuals.

Teleconference Focuses on Cancer Survivorship Research
"Cancer Survivorship Research: A Dialogue with Advocates, Survivors, and Caregivers," the final teleconference for the fall 2007 Understanding NCI series, sponsored by NCI's Office of Advocacy Relations (OAR), will take place December 11 from 1:00-2:00 p.m., ET.

Dr. Julia Rowland, director of NCI's Office of Cancer Survivorship (OCS), will highlight cancer survivorship research and Lourie Campos, a member of the NCI Director's Consumer Liaison Group, will discuss her role in working with OCS to plan the annual cancer survivorship conference. The teleconference can be accessed toll free within the U.S. at 800-857-6584; the passcode is OCS. Toll-free playback will be available through January 11 at 800-253-1052. For more information contact OAR at 301-594-3194 or

NCAB Meeting Held
The National Cancer Advisory Board (NCAB) met on November 27 in Bethesda, MD. The meeting agenda and videocast are available online.

NCI and AACR Sponsor Meeting on Cancer Health Disparities
NCI's Center to Reduce Cancer Health Disparities joined the American Association for Cancer Research (AACR) in Atlanta on November 27-30 for a meeting on the "Science of Cancer Health Disparities." The meeting was cosponsored by NCI and AACR and is the first time that the organizations have collaborated on a national meeting to address this issue. Additional information about the meeting is available at